# Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients

> **NCT04140201** · PHASE4 · UNKNOWN · sponsor: **Alaa Hassan ElBaz** · enrollment: 80 (estimated)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Simvastatin 40mg
- **DRUG:** Fenofibrate 200mg
- **DRUG:** Omega 3 fatty acid

## Key facts

- **NCT ID:** NCT04140201
- **Lead sponsor:** Alaa Hassan ElBaz
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02
- **Primary completion:** 2020-06
- **Final completion:** 2020-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04140201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04140201, "Effect of Lipid Lowering Agents on Diabetic Retinopathy and Cardiovascular Risk of Diabetic Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04140201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*